Cargando…

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19

Detalles Bibliográficos
Autores principales:	Graziani, Lucia, Gori, Leonardo, Manciulli, Tommaso, Basile, Gregorio, Campolmi, Irene, Borchi, Beatrice, di Dio, Marta, Mattei, Marta, Ciurleo, Greta, Ciliberti, Maria, Malentacchi, Francesca, Coppi, Marco, Morettini, Alessandro, Parronchi, Paola, Rossolini, Gian Maria, Bartoloni, Alessandro, Tomassetti, Sara, Spinicci, Michele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890247/ https://www.ncbi.nlm.nih.gov/pubmed/36544352 http://dx.doi.org/10.1093/jac/dkac433

Ejemplares similares

Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature
por: Marangoni, Davide, et al.
Publicado: (2023)

Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy
por: Manciulli, Tommaso, et al.
Publicado: (2022)

Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol
por: Vellere, Iacopo, et al.
Publicado: (2021)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
por: Manciulli, Tommaso, et al.
Publicado: (2021)

Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients
por: Catalán, Ignacio Pérez, et al.
Publicado: (2022)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications
por: Spinicci, Michele, et al.
Publicado: (2022)

Clinical and Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary Care Center
por: Spinicci, Michele, et al.
Publicado: (2021)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Scalp eschar and neck lymph adenopathy after a tick bite (SENLAT) in Tuscany, Italy (2015–2022)
por: Barbiero, Anna, et al.
Publicado: (2023)

High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
por: Huygens, Sammy, et al.
Publicado: (2023)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)

Implementing Early Phase Treatments for COVID-19 in Outpatient Settings: Challenges at a Tertiary Care Center in Italy and Future Outlooks
por: Manciulli, Tommaso, et al.
Publicado: (2022)

AIDS patient with severe T cell depletion achieved control but not clearance of SARS‐CoV‐2 infection
por: Spinicci, Michele, et al.
Publicado: (2021)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

Extreme disparities in the access to outpatient treatment for COVID-19 observed at a tertiary hospital in Florence, Tuscany, Italy
por: Gaggioli, S., et al.
Publicado: (2023)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022)

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
por: Blair, Hannah A.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_av3re1l5i84k7l75m368oiar94